# Gyre Therapeutics (GYRE) — Overview

GYRE · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/gyre

## Price

Last close $6.40 on Oct 15, 2026. 52-week range $5.56 – $8.87.

## Company profile

Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

## Financials

| Metric | Value |
| --- | --- |
| Revenue (trailing twelve months) | $109.8M |
| Revenue (quarter) | $29.1M |
| Revenue growth (year over year) | -2.12% |
| Gross profit (trailing twelve months) | $103.0M |
| Gross margin | 93.80% |
| Net income (trailing twelve months) | −$25.7M |
| Net income (quarter) | −$14.3M |
| Net income growth (year over year) | -537.91% |
| Net margin | -23.38% |
| Return on equity | -17.90% |
| EPS (trailing twelve months) | −$0.20 |
| Book value per share | $1.23 |
| P/E (trailing twelve months) | — |
| Price to book | 4.3 |
| Debt to assets | 17.23% |
| Payout ratio | -9.75% |
| Dividend yield | 0.00% |

## Frequently Asked Questions

### Is Gyre Therapeutics (GYRE) profitable?

No. Gyre Therapeutics reported a net loss of $25.7M over the trailing twelve months.

### How much revenue does Gyre Therapeutics (GYRE) make?

Gyre Therapeutics generated $109.8M in revenue over the trailing twelve months, down 2.12% year over year.

### How do I buy stock in Gyre Therapeutics (GYRE)?

GYRE trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at [Light Horse Dashboard](https://portal.lighthorse.io), the trading API, or an [AI agent connected over MCP](/instructions/ai/claude). The trade panel on this page places the order once you are signed in.

---

Quotes and charts are not real-time and must not be relied on for trade decisions or valuation.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).